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EFFICACY OF THREE NONPHARMACOLOGICAL INTERVENTIONS 
FOR ALZHEIMER’S DISEASE   
AARON ARTILES 
ABSTRACT 
The leading cause of dementia globally is Alzheimer’s disease, and its incidence 
is increasing.  Besides the immense clinical impact on the afflicted patient, Alzheimer’s 
disease has a significant social impact on the patient’s family and friends.  
Pharmacological interventions have shown modest results and are lacking in successful 
disease-modifying therapies.  Three of the most common nonpharmacological 
interventions for Alzheimer’s disease are cognitive, exercise, and nutritional methods.  
The goal of this study was to analyze the efficacy of these interventions in an effort to 
uncover the most promising nonpharmacological strategies with which to utilize moving 
forward. 
This thesis reviewed a large number of studies evaluating different cognitive, 
exercise, and nutritional interventions for patients suffering from Alzheimer’s disease.  
The review considered each study by looking at both the methods used and the results 
obtained.  The cognitive intervention studies revealed modest results, with cognitive 
rehabilitation being the most promising cognitive intervention.  Exercise interventions 
showed positive results for the patients’ activities of daily living and quality of life.  
Although nutritional interventions produced modest improvements, the Mediterranean 
diet had the most encouraging results. 
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Based on the analysis of these studies, this thesis concludes that cognitive 
rehabilitation, exercise, and the Mediterranean diet are the most effective 
nonpharmacological interventions for managing patients with Alzheimer’s disease in the 
future. 
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INTRODUCTION 
 
Alzheimer’s Disease 
 Approximately 10% of people over 70 years of age have substantial loss of 
memory.  In the majority of these cases, Alzheimer’s disease (AD) is the cause.  It has 
been estimated that the total cost of providing care for a patient suffering from AD 
exceeds $50,000 without including the significant toll it takes on the people closest to the 
patient (Seeley & Miller, 2015).  There is an excess of 35 million people who are 
suffering from dementia today.  Projections indicate this number will increase to 70 
million within 20 years.   Dementia is the number one causative factor for the aging 
population to become disabled.  In 2010, it was estimated the overall global cost of 
dementia exceeded $600 billion, and with the growing aging population, this number is 
only going to increase.  However, the emergence of novel and less expensive treatments 
for Alzheimer’s disease and dementia may potentially decrease this cost (Wimo, Jönsson, 
Bond, Prince, & Winblad, 2013).   
 There are three main disease stages observed in patients with AD: early/mild, 
middle/moderate, and late/advanced (Seeley & Miller, 2015).  Mild Cognitive 
Impairment (MCI) precedes early stage AD; however, approximately half of the patients 
with MCI eventually acquire AD.  The natural progression of Alzheimer’s disease 
usually begins with a gradual decrease in episodic memory, which leads to dementia that 
slowly worsens while the disease takes its course.  The first presentation of the disease is 
the insidious increase in forgetfulness and is classified as ‘early’ with a Mini-Mental 
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State Examination (MMSE) score of approximately 20-24 (“Tests for Alzheimer’s & 
Dementia,” n.d.).  Occurrences of everyday life start to be forgotten and the names of 
people that are not well known become hard to remember for the patient.  The patient 
may begin to lose objects, and occasionally scheduled appointments may be missed.  
Later on, the patient may ask the same question repeatedly, and he or she may forget 
conversations that just occurred or topics that were recently discussed (Ropper, Samuels, 
& Klein, 2014).  To some extent, recent memories are forgotten whereas memories of the 
distant past are preserved; however, memory loss can extend to distant memories as well.  
As the disease progresses to moderate (MMSE score 13-20), it affects more than just the 
patient’s memory (“Tests for Alzheimer’s & Dementia,” n.d.).  For example, speech is 
affected, and the afflicted patient begins to have slurred speech.  This disability in speech 
also extends to writing, and the patient may begin to misspell words more often (Ropper 
et al., 2014).  Normal activities, such as controlling finances, navigation, following 
instructions, and household chores, are often impaired.  However, activities that follow a 
routine as well as superficial social interactions can be maintained even as the disease 
becomes more severe (Seeley & Miller, 2015).     
 After years of decline, the patient’s language skills begin to deteriorate 
significantly, and he or she may no longer be able to speak in complete sentences or 
much at all.  This is the advanced stage (MMSE less than 12) (“Tests for Alzheimer’s & 
Dementia,” n.d.).  Similar to speaking and reading skills, arithmetic abilities deteriorate 
(Ropper et al., 2014).  As the disease continues to progress, it is likely that the patient’s 
personality is altered, and the patient may become either more sedentary or overactive.  
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About 30% of patients with AD develop depression during the course of the disease.  As 
AD proceeds, patients may develop incontinence and become much more reliant on 
others to perform activities of daily living (ADL) (Carlsson, Gleason, Puglielli, & 
Asthana, 2009).  The most routine and automatic movements are the only actions that the 
patient maintains (Ropper et al., 2014).  The most common causes of death for patients in 
the last stages of AD are aspiration pneumonia, dehydration, malnutrition, pulmonary 
embolism, heart disease, or a secondary infection.  The typical duration from the onset of 
AD to death is usually eight to ten years, but the time can be significantly shorter or 
longer (Seeley & Miller, 2015). 
 During the late stages of AD, the brain atrophies to a weight that is approximately 
80% of what it used to be.  The atrophy is most prominent in the frontal and temporal 
lobes of the brain, but other areas can atrophy as well (Ropper et al., 2014).  The 
pathology of AD is characterized by the presence of neuritic plaques and neurofibrillary 
tangles (Figure 1).  These plaques are caused by the accumulation of amyloid-beta (Aβ) 
peptide, whereas the neurofibrillary tangles are the result of hyperphosphorylated tau 
protein that accumulates inside neurons (De-Paula, Radanovic, Diniz, & Forlenza, 2012).  
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Figure 1. Pathology of Alzheimer’s disease.  This slide shows a sample of cortex taken 
from the brain of a patient with AD.  The three arrowheads (A) point to a neuritic plaque 
showing extracellular deposits of Aβ peptide.  Arrow B points to a neuron containing 
neurofibrillary tangles.  (Figure taken from Carlsson et al., 2009). 
 
 
Amyloid precursor protein (APP) is the protein responsible for the formation of 
Aβ peptide in brain tissue.  APP is a transmembrane protein that is largely expressed 
throughout the central nervous system (CNS) (De-Paula et al., 2012).  Aβ peptide ranges 
in size from 39 to 42 amino acids in length (Seeley & Miller, 2015).  The Aβ peptides 
with lengths of 40 and 42 amino acids, Aβ40 and Aβ42, respectively, are the most common 
B	
A	
A	
A	
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Aβ peptides found in the brain.  Aβ42 is the peptide that is most prone to aggregation in 
the brain tissue to form neuritic plaques.  Therefore, this peptide is the most important in 
understanding the pathogenesis of AD (De-Paula et al., 2012).   
The transmembrane protein APP is cleaved in two distinct pathways (Figure 2).  
The first pathway is the secretory pathway, which is normal and does not cause the 
aggregation of Aβ peptide.  In this non-amyloidogenic pathway, the APP protein is 
cleaved in sequence by α-secretase and then by γ-secretase (De-Paula et al., 2012).  The 
α-secretase cleaves APP inside the region that makes up the Aβ peptide; therefore, the Aβ 
peptide cannot be formed (Braak & Braak, 1998).  If the APP protein is instead cleaved 
by β-secretase and then γ-secretase before it can be cleaved by α-secretase, Aβ40 and Aβ42 
peptides can be released into the extracellular fluid (Selkoe, 2011).  Although the Aβ 
peptide is secreted from the cell as a monomer, in the disease state the protein aggregates 
with other monomers to form oligomers (De-Paula et al., 2012). 
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Figure 2. Cleavage of APP by α-, β-, and γ-secretase.  In the first step, APP can be 
cleaved by either α-secretase or β-secretase.  If APP is cleaved by α-secretase and then by 
γ-secretase, a nontoxic product (P3) is formed.  However, if APP is cleaved by β-
secretase followed by γ-secretase, the toxic Aβ42 can be formed, potentially contributing 
to the formation of neuritic plaques.  (Figure amended from Seeley & Miller, 2015) 
 
 
 
 
The second type of pathological lesion found in AD is the neurofibrillary tangle 
(NFT) (Figure 1, Arrow B).  These lesions occur independently from the neuritic plaques 
that are caused by Aβ42 in patients with AD (Selkoe, 2011).   NFTs are found in the 
cytosol of neurons rather than in the extracellular matrix where amyloid plaques occur 
(Carlsson et al., 2009).  When the tau protein becomes abnormally phosphorylated, it can 
no longer perform its normal function of stabilizing microtubules for neuronal transport 
down the axon (Figure 3).  Because tau no longer stabilizes the microtubules, neuronal 
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transport is affected, and NFTs can be found in the cytoplasm as a result of the 
accumulation of phosphorylated tau (Seeley & Miller, 2015).  NFTs are seen as paired 
filaments, and the aggregates have ubiquitin incorporated into them.  Ubiquitination may 
be an attempt by the neuron to take care of the NFTs through proteolysis; however, this 
process is not successful.  Eventually, the accumulation of NFTs causes the neuron to 
lose its function, resulting in the death of the cell (Selkoe, 2011).    
 
      
 
 
 
Figure 3. Neurofibrillary tangle formation.  The protein tau helps to stabilize 
microtubules within the cytosol (left).  When tau becomes hyperphosphorylated, it is no 
longer able to perform this function.  The microtubule becomes destabilized, and tau 
aggregates into paired filaments (right).  (Figure taken from Selkoe, 2011) 
 
 
 
  
	8 
Pharmacological Treatment for Alzheimer’s Disease 
 A failure in the brain’s cholinergic system has long been suggested as one of the 
causes of AD (Hogan, 2014).  The efficacy of cholinesterase inhibitors to treat the 
symptoms of Alzheimer’s disease has been well documented within the literature 
(Borisovskaya, Pascualy, & Borson, 2014).  The three most widely administered 
cholinesterase inhibitors are donepezil, galantamine, and rivastigmine (Jellinger, 2007).  
These three drugs exhibit a clinically significant effect on the symptoms of the disease 
without having an effect on the underlying pathogenesis (Jellinger, 2007).  For example, 
in the two-year study on galantamine by Hager et al. (2014), a lower mortality rate was 
observed in the group administered galantamine compared to the placebo group.  Also, 
the patients treated with galantamine showed less cognitive deterioration, as described by 
mean Mini-Mental State Examination (MMSE) scores (Figure 4), and an increase in 
activities of daily living (Hager et al., 2014).  Similarly, in the study performed by 
Richarz, Gaudig, Rettig, and Schauble (2014), a cognitive benefit to galantamine 
treatment was observed in patients with mild to moderate Alzheimer’s disease.  
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Figure 4. Mean change in Mini-Mental State Examination scores over time.  The 
group administered galantamine shows an initial increase in MMSE scores after the first 
six months.  Significant differences are seen between the two control and AD groups in 
MMSE scores for all time points after baseline.  SE = standard error.  (Figure taken from 
Hager et al., 2014) 
 
 
 
There have been concerns raised about possible adverse effects of cholinesterase 
inhibitors, including bradycardia, syncope, bronchoconstriction, and weight loss (Hogan, 
2014).  Borisovskaya et al. (2014) reported gastrointestinal consequences such as 
vomiting, nausea, and diarrhea as likely adverse effects of cholinesterase inhibitors.   
In more severe stages of AD, memantine in combination with cholinesterase 
inhibitors has been shown to be effective (Jellinger, 2007).  Unlike cholinesterase 
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inhibitors which affect the cholinergic system of the brain, memantine affects the 
glutaminergic system (Borisovskaya et al., 2014).  Memantine is an antagonist of the N-
methyl-D-aspartate (NMDA) receptor (Waite, 2015).  In the study by Dysken et al. 
(2014), memantine was shown to have no effect in patients with mild to moderate AD 
compared with the study’s placebo group.  On the other hand, in patients with moderate 
to severe AD, a significant benefit of memantine was documented, showing 
improvements in ADL, cognition, and behavior (Waite, 2015).  Nevertheless, it has been 
argued that the economic cost of memantine is not worth the meager benefit of the drug 
for patients with AD (Waite, 2015).  Cholinesterase inhibitors and memantine are the 
only major pharmacological treatment options for patients with AD.  These interventions, 
however, only treat the symptoms of the disease and do not alter the disease-causing 
lesions (Chu, 2012).  Pharmacological interventions for this purpose are currently in 
clinical trials (Chu, 2012).   
More recently, novel anti-amyloid immunotherapy strategies have been 
developed.  The study by Schenk et al. in 1999 was the first study using a transgenic 
animal model to show that through immunization with Aβ42 there was a significant 
reduction or absence of amyloid plaques.  With the use of mouse models, this study was 
able to demonstrate a possible benefit to anti-amyloid immunotherapy (Schenk et al., 
1999).  This strategy, called passive immunotherapy, used monoclonal antibodies to 
target Aβ peptide in the hope to inhibit Aβ peptide aggregation and increase peptide 
removal.  Passive immunotherapy remains to be the most effective disease-modifying 
intervention for AD (Rafii & Aisen, 2015).   
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There have been other trials using different monoclonal antibodies targeting Aβ 
peptide with varying degrees of success.  In the 2014 phase III clinical trials by Doody et 
al., there was a trend that solanezumab, a monoclonal antibody, caused an increase in 
cognition in patients with mild AD in one of the two trials.  This finding, however, lacked 
statistical significance.  When patients in both trials were pooled together, the benefit of 
solanezumab was significant (Doody et al., 2014).  In a clinical trial with crenezumab, 
another monoclonal antibody, there was a trend that the drug showed a slowing of 
cognitive decline in patients with mild AD (Rafii & Aisen, 2015).  Finally, gantenerumab 
is another monoclonal antibody that binds to Aβ peptide with high affinity (Bohrmann et 
al., 2012).  In a phase II clinical trial of gantenerumab started in 2012, the testing was 
ceased in 2014 because of the lack of efficacy of the drug (Rafii & Aisen, 2015). 
 
Specific Aims and Objectives 
 Because of the economic and social costs of treating AD using pharmacological 
methods, as well as the modest benefit gained from these interventions, it is imperative to 
examine other treatment options for patients with AD.  Therefore, this thesis will explore 
the efficacy of three nonpharmacological approaches to treat patients with AD: cognitive, 
exercise, and nutritional interventions.  
 The aims of this thesis are: 
1. Analyze separately the efficacy of three nonpharmacological interventions for 
AD: cognitive, exercise, and nutritional interventions. 
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2. Based on the literature, decide if there is significant evidence of positive 
effects with these nonpharmacological interventions. 
3. Analyze the practicality of using any of the three nonpharmacological 
interventions to treat patients with AD. 
4. Propose future directions using one or more nonpharmacological interventions 
for AD. 
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PUBLISHED STUDIES 
 
 The many studies performed on the pharmacological interventions for AD show a 
reduction of symptoms; however, these positive results are modest (Olazarán et al., 
2010).  There are a number of pharmacological agents that have been targeted to reverse 
or slow the deterioration in AD, including donepezil, huperzine A, and cholinesterase 
inhibitors (Rodakowski, Saghafi, Butters, & Skidmore, 2015).  These treatments have not 
been able to correct the long-term result of cognitive decline characteristic of AD 
(Rodakowski et al., 2015). 
 Therefore, there is a need for studies assessing nonpharmacological interventions 
as an alternative approach.  In addition, because of the current economic and societal cost 
of AD, the need for nonpharmacological interventions has become critical (Olazarán et 
al., 2010).  There are a number of benefits from using nonpharmacological interventions 
rather than the current pharmacological approaches to treat AD.  In particular, there are 
limited adverse side-effects from these interventions as opposed to those seen in 
pharmacological treatments (Rodakowski et al., 2015).  Cholinesterase inhibitors, for 
example, show side-effects including bradycardia, syncope, bronchoconstriction, and 
weight loss (Hogan, 2014).   
 Three of the most widely studied nonpharmacological interventions for 
Alzheimer’s disease are cognitive, exercise, and nutritional interventions. 
  
	14 
Cognitive Interventions for Patients with Alzheimer’s Disease 
 For the past 30 years, there has been more research evaluating cognitive 
intervention techniques for the treatment of patients with AD.  Cognitive interventions 
typically involve training to improve cognitive abilities and function.  The end goal of 
this intervention is to delay or prevent the cognitive decline characteristic of AD 
(Acevedo & Loewenstein, 2007).  There are three types of cognitive interventions that 
are generally found in the literature: cognitive training (CT), cognitive stimulation (CS), 
and cognitive rehabilitation (CR) (Borisovskaya et al., 2014).  The three treatment 
strategies are described in Table 1. 
 
Table 1. Types of cognitive intervention.  Abbreviations – ADL: activities of daily 
living and IADL – instrumental activities of daily living  (Table taken from Borisovskaya 
et al., 2014) 
 
 
 
  
	15 
In the randomized control trial by Davis, Massman, and Doody in 2001, a 
combination of different cognitive interventions were tested and compared to a control 
group.  The study used 27 patients diagnosed with probable AD.  The cognitive 
intervention consisted of face-name training, spaced retrieval, and cognitive stimulation.  
These strategies were the most promising cognitive interventions at the time.  Spaced 
retrieval is a cognitive intervention performed by asking the patient to recall something 
over increasingly longer and longer periods of time.  This method had previously been 
found to increase the patient’s memory of objects.  The placebo group went through 
intervention consisting of conversation, videotapes, and studying previously learned 
material (Davis et al., 2001). 
 This study by Davis et al. (2001) showed some differences between the 
experimental and control groups; however, the results did not strongly support the 
hypothesis that patients might show improved overall recall as well as 
neuropsychological functioning and quality of life.  Although the experimental group 
exhibited improved recall, Davis noted that the intervention did not produce any 
beneficial effects in the experimental group relating to depression, motor speed, visual or 
verbal memory, word generation, dementia severity, or patient quality of life.  
Furthermore, there was no change in Mini-Mental State Examination (MMSE) scores 
(Davis et al., 2001).  The MMSE assesses 20 different areas of cognitive functioning, 
such as language, attention, and visuospatial skills (Small, Viitanen, & Bäckman, 1997).            
 In the study by Cahn-Weiner, Malloy, Rebok, and Ott in 2003, similar results 
were reported.  The researchers noted that there may be beneficial effects to using 
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cholinesterase inhibitors in combination with a cognitive training intervention.  
Therefore, 34 patients with probable AD, who were also taking cholinesterase inhibitors, 
were assigned to a cognitive training group or a control group.  The purpose of the study 
was to measure the neuropsychological condition of the patients before and after the 
intervention as well as ADL and memory assessed by caregivers.  The experimental 
group went through a six-week memory-training program consisting of categorization 
and visualization.  The control group participated in a six-week intervention consisting of 
discussions without memory-training exercises (Cahn-Weiner et al., 2003). 
 The results of the Cahn-Weiner et al. (2003) study were very similar to the results 
of the Davis et al. (2001) study.  No neuropsychological, ADL, or “everyday memory 
function” benefits were found during the study (Cahn-Weiner et al., 2003).  The only 
improvement was in the patient’s ability to recall words from the word lists used during 
the tests (Cahn-Weiner et al., 2003).  This was similar to the findings of Davis and his 
colleagues (Davis et al., 2001) who found that there was a significant difference in the 
patient’s ability to recall information before and after the cognitive intervention.   
 Next, the study by Olazarán et al. in 2004 set out to investigate the effects of a 
cognitive motor intervention (CMI) that consisted of “cognitive exercises, plus social and 
psychomotor activities.”  The experimental group receiving the CMI was tested against 
the control group receiving psychosocial support without the cognitive interventions.  
Seventy-five patients taking cholinesterase inhibitors with mild cognitive impairment 
(MCI) or probable AD were divided into two groups, 38 in the control group and 37 in 
the experimental group (Olazarán et al., 2004). 
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 This study by Olazaran et al. (2004) assessed the benefits of CMI by looking at 
the changes in the cognitive subscale of the AD Assessment Scale (ADAS-cog) as well as 
MMSE, ADL using a questionnaire, and geriatric depression using the Geriatric 
Depression Scale (GDS).  ADAS-cog measures “memory, language, ideational praxis, 
and visuospatial ability.”  Patients in the experimental group were able to maintain their 
ADAS-cog measure through the first 6 months of treatment, whereas the control group 
showed deterioration in this category.  In addition, at 12 months the experimental group 
exhibited a beneficial increase in their GDS scores.  Furthermore, the results of the study 
indicated a trend that MMSE scores and ADL scores in the experimental group did not 
deteriorate as dramatically over the course of the year as they did in the control group.   
The results showed some evidence of a possible beneficial effect of cognitive 
interventions on mood and cognition (Olazarán et al., 2004). 
 The 2004 trial by Loewenstein, Acevedo, Czaja, and Duara was an attempt at 
combining multiple cognitive intervention strategies into one training program.  Twenty-
five patients received cognitive training that consisted of face-name associations, time 
and place orientation, procedural and motor memory exercises, exercises in maintaining 
attention, and training in useful functional skills like making change and paying bills.  
The 19 patients in the control group went through “mental stimulation training” during 
which they played computer games with memory exercises and word games.  As in the 
studies previously discussed, all of the participants were taking cholinesterase inhibitors 
at the time of the study (Loewenstein et al., 2004).   
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 The results of the Loewenstein et al. (2004) study showed some beneficial results 
from the cognitive training intervention in comparison with the mental stimulation 
control group.  These results, including better face-name associations, orientation, and 
functional skills, suggested that cognitive interventions could have beneficial effects on 
real-world tasks, possibly improving quality of life and ADL (Loewenstein et al., 2004).  
 In the 2010 study by Niu, Tan, Guan, Zhang, and Wang, the effect of a cognitive 
stimulation (CS) therapy was tested.  Thirty-two patients with probable AD were enrolled 
in the study with 16 patients in the experimental cognitive stimulation group and 16 
patients in the control group.  All of the participants in the study were taking 
cholinesterase inhibitors before and during the study.  The cognitive stimulation consisted 
of specific tasks exercising the patient’s executive functioning and working memory.  
The control group underwent a placebo therapy consisting of “communication exercises.”  
According to the results, the experimental group receiving cognitive stimulation showed 
improved neuropsychiatric symptoms, whereas the group receiving the placebo treatment 
showed a decline.  Similarly, the MMSE scores of the cognitive stimulation group 
increased, whereas the scores of the placebo group decreased.  The results of this study 
indicated that cognitive stimulation therapy could improve cognition, apathy, and 
depression in AD patients taking cholinesterase inhibitors (Niu et al., 2010). 
 The 2010 study by Clare et al. designed to study the effects of a cognitive 
rehabilitation (CR) program was completed.  Unlike cognitive stimulation or cognitive 
training, cognitive rehabilitation takes an individualized approach.  In order to do this, 
patients and families work with healthcare providers to devise a cognitive intervention 
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based on each patient’s needs and goals.  Clare and her colleagues argued that CR was a 
better approach than other more standardized cognitive interventions because every 
patient has different requirements that need to be addressed.  In this study, the researchers 
compared CR with a relaxation therapy (RT) group and a no-treatment (NT) control 
group.  The study involved 69 patients who were diagnosed with AD and prescribed 
cholinesterase inhibitors.  Each patient in the CR group focused on one or two goals 
during the intervention and was told to keep working on goals outside of the eight one-
hour sessions (Clare et al., 2010).   
 The results of the Clare et al. (2010) study showed beneficial results for cognitive 
rehabilitation.  For example, patient scores for goal performance and satisfaction 
improved after the CR intervention compared with the relaxation therapy and no-
treatment groups.  Also at the follow-up six months after the conclusion of the study, 
patients in the CR group rated their memory performance higher than the patients in the 
no-treatment group.  Although the beneficial findings in this study were significant, it 
was difficult to determine whether they were clinically relevant (Clare et al., 2010). 
 The 2015 study by Kim also set out to study a cognitive rehabilitation (CR)  
intervention.  Similar to the study by Clare et al. (2010), this cognitive intervention was 
individualized to each patient and was goal-oriented (Kim, 2015).  However, Kim’s study 
was different from that of Clare et al. (2010) in that it incorporated cognitive training 
techniques into the cognitive rehabilitation intervention (Kim, 2015).  The goal of the 
study was to see if CR in combination with some aspects of CT could improve the daily 
lives of patients with AD.  To do this, 43 patients diagnosed with AD were assigned 
	20 
randomly to a CR group and a control group.  All patients participated in eight hour-long 
sessions of either CR or a control therapy depending on their group.  The CR was 
centered on a personal goal of the patient and also included some cognitive training 
exercises (Kim, 2015).   
 The results of the study by Kim (2015) were very similar to the results found by 
Clare et al. (2010).  Improvements were observed in patient performance and satisfaction 
in the CR group.  In addition, the CR group showed improvements in performance, 
quality of life, and the orientation subscale of the MMSE.  No improvements were 
observed in the control group post-intervention.  The results of this study indicated that 
CR could benefit patients with early-stage AD and that it could be effective in helping 
these patients with real-life activities (Kim, 2015). 
 
Exercise Interventions for Patients with Alzheimer’s Disease 
 It has become apparent that physical exercise is necessary for brain health, 
especially in the elderly.  Exercise-induced beneficial changes in the brain with respect to 
memory, executive functioning, and attention have been well documented in the literature 
(Kirk-Sanchez & McGough, 2014).  It has also been found that physical exercise can 
have a protective effect against cognitive decline and can reduce the risk of cognitive 
impairment (Ahlskog, Geda, Graff-Radford, & Petersen, 2011).  Furthermore, it has been 
reported that maintaining an exercise program can reduce mortality and extend the lives 
of patients with AD.   This trend is visualized in the survival curves obtained by 
Scarmeas et al. (2011) (Figure 5). 
	21 
 
 
 
Figure 5:  Activity level survival curves.  These curves show mortality rates of a cohort 
of patients with Alzheimer’s disease following three different levels of physical activity. 
(Figure taken from Scarmeas et al., 2011)   
  
 
The study by Cot, Dawson, Sidani, and Wells in 2002 examined the possible 
beneficial effects of a walking and talking intervention for the treatment of patients with 
AD in a nursing home.  These participants were divided into three groups: a “walk-and-
talk group,” a “talk-only group,” and a group that received no intervention.  Participants 
who were assigned to the walking and talking group received a 16-week intervention 
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where they walked and talked for 30 minutes, five times every week.  Participants 
assigned to the “talk-only group” conversed with one other person for 30 minutes, five 
times each week for 16 weeks.  Finally, the control group received no intervention.  A 
total of 90 nursing home residents were used in this study with 30 AD patients in each of 
the groups.  The purpose of this study was to find a possible beneficial effect of the 
walking and talking intervention on the resident’s level of function, ability to 
communicate, and ability to ambulate (Cott et al., 2002).   
 The results of the Cott et al. (2002) study showed no benefits for the patients 
assigned to the walking and talking intervention.  In fact, there were no significant 
differences found between any of the three groups after the completion of the 
intervention.  The outcome of this study indicated that there was no effect of the 
intervention on the patient’s ability to communicate, ability to ambulate, or functional 
status.  Cot and colleagues argued that this result may be due to the fact that the AD 
patients enrolled in the study were at an advanced stage of the disease.  Previous studies 
had found beneficial effects for AD patients that were less impaired with respect to 
ambulation and communication abilities (Cott et al., 2002). 
 The study by Rolland et al. in 2007 similarly used nursing home patients to test an 
exercise intervention.  The exercise intervention involved walking, strength training, 
balance training, and flexibility training.  The intervention lasted a total of 12 months and 
consisted of one-hour sessions, two times a week.  A total of 134 patients with AD were 
separated into two groups, with one receiving the exercise intervention and the other 
receiving routine medical care.  Participants’ activities of daily living performance, 
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physical performance, nutrition, behavioral disturbances, and depression were assessed.  
Normally, AD causes a decline in a patient’s capacity to perform activities of daily living.  
Therefore, an intervention that slowed this decline could prove clinically relevant.  In 
addition, nursing home residents are often more inactive than patients outside of a 
nursing home, so an exercise program might be even more important for them (Rolland et 
al., 2007).   
 Although there was a decline in the ability to perform ADLs over the 12-month 
study period for patients in both the experimental and control groups, the AD patients in 
the experimental group declined only one-third as much as the patients in the control 
group (Rolland et al., 2007).  Furthermore, Rolland and colleagues observed a significant 
correlation between the number of exercise sessions completed and deterioration in the 
capacity to perform ADLs (Figure 6).  In addition, there was a significant improvement in 
walking speed for the experimental group at both 6 months and 12 months after the start 
of the intervention.  However, there was no significant improvement in nutrition, 
depression, or behavioral disturbance (Rolland et al., 2007). 
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Figure 6. ADL and exercise adherence.  This plot shows a significant Spearman 
correlation (r) between more exercise sessions attended and less drastic decline in the 
capacity to perform activities of daily living (ADL).  P = statistical significance.  (Figure 
taken from Rolland et al., 2007)  
 
 
 Next, in the 2008 study by Miu, Szeto, and Mak, an exercise intervention was 
tested for patients with dementia in the hope of uncovering beneficial effects on physical 
function, cognition, and affect.  The exercise intervention consisted of aerobic training on 
treadmill and bicycle, flexibility training, and ergometry.  The exercise sessions lasted for 
one hour and occurred two times a week for 12 weeks.  Of the 85 patients with dementia 
who participated in this study, 61% had AD, whereas the remaining 39% had other types 
of dementia.  Thirty-six patients were assigned to the exercise intervention, and 49 
patients were assigned to the control group that received routine medical treatment.  
Fifty-four of these patients were taking cholinesterase inhibitors.  Patient assessments 
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occurred every 2 months for 12 months, and both cognitive and physical tests were given 
(Miu et al., 2008). 
 The results of the study by Miu and colleagues indicated that the exercise 
intervention had an effect on the physical function of the dementia patients but no effect 
on cognition (Miu et al., 2008).  Although the exercise intervention only lasted for 12 
weeks, the experimental group was able to maintain or improve in all physical 
assessments after 12 months, whereas the control group showed deterioration.  Therefore, 
even though Miu’s study did not demonstrate that exercise affected cognition, it found 
that an exercise program could have an effect on ADL and physical function in patients 
with dementia, including patients with AD (Miu et al., 2008). 
 The pilot study in 2009 by Steinberg, Leoutsakos, Podewils, and Lyketsos 
evaluated another exercise intervention for patients with AD still living at home.  
Twenty-seven patients diagnosed with probable AD were assigned to either the exercise 
intervention group, consisting of aerobic exercise as well as strength training and balance 
and flexibility training, or the control group, receiving a home safety assessment.  The 
main objective of Steinberg’s study was to assess the effects of exercise intervention on 
the participants’ physical functioning, but effects on cognition, neuropsychiatric 
symptoms, and quality of life also were evaluated.  The study demonstrated trends 
indicating that the experimental group improved on a test for hand function, predictive of 
ability to perform ADLs, as well as a test for leg strength.  No benefits of the exercise 
intervention were detected in cognition, neuropsychiatric symptoms, or quality of life 
(Steinberg et al., 2009). 
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 In a study in 2011, Venturelli, Scarsini, and Schena tested an exercise intervention 
on patients with advanced stages of AD.  All of the patients were currently living in a 
nursing home.  The exercise intervention consisted of 30 minutes of walking, four times 
each week.  Twenty-one patients were assigned to an exercise intervention group or a 
control group consisting of nursing home social activities (e.g., bingo and sewing).  The 
walking intervention lasted 24 weeks, and patients were assessed at baseline and 
following the completion of the intervention.  Patients were assessed on their ability to 
perform ADLs and physical functions, and global cognition.  Venturelli and colleagues 
wanted to determine whether the walking intervention had a beneficial effect on the 
deterioration caused by late stage AD (Venturelli et al., 2011).   
 The results of Venturelli’s study showed positive results for the group receiving 
the exercise intervention (Venturelli et al., 2011).  After the 24-week intervention, the 
experimental group showed a significant improvement in the distance they could walk in 
six minutes, whereas the control group showed a decline in their performance on this 
walking test.  In addition, the experimental group demonstrated a significant 
improvement in their ability to perform ADLs, even though the control group neither 
improved nor declined.  Finally, the experimental group was able to maintain its MMSE 
score after the 24-week intervention, whereas the control group showed a decline on this 
global cognition score (Venturelli et al., 2011).   
 The exercise program tested by Vreugdenhil, Cannell, Davies, and Razay in 2012 
consisted of a daily exercise routine with 10 different exercises for lower and upper body 
strength and balance.  These exercises were in addition to 30 minutes of brisk walking.  
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Forty patients living with AD were divided into two groups: one receiving this exercise 
intervention lasting for four months and one receiving routine medical care as control.  
Participants in the experimental group exercised daily.  The purpose of Vreugdenhil’s 
study was to see if there was a beneficial effect of the exercise program on cognition, 
ability to perform ADLs, physical function, depression, global change in function, and 
caregiver burden (Vreugdenhil et al., 2012).   
 The results of the study by Vreugdenhil and his colleagues showed that when 
comparing them with the control group, the group receiving the exercise intervention 
improved in cognition, physical function, and ability to perform ADLs (Vreugdenhil et 
al., 2012).  Moreover, a trend observed indicated improvement on the depression scale 
and assessment of caregiver burden.  These results suggested that a daily exercise 
program could benefit cognition, physical function, and ability to perform ADLs in AD 
patients (Vreugdenhil et al., 2012). 
 Likewise, the 2015 pilot study by Holthoff et al. implemented an exercise 
program on AD patients living at home.  Thirty patients participated in the study, all of 
whom were diagnosed with AD.  All of the patients in the study were taking 
cholinesterase inhibitors, memantine, or both drugs.  The exercise program consisted of 
physical activity using a bicycle ergometer and lasted for 12 weeks.  The patients 
exercised three times each week for 30-minute sessions.  Patients were assessed in 
physical functioning, ADL, clinical symptoms, and caregiver burden at 12 weeks when 
the study concluded and at 24 weeks for a follow-up assessment (Holthoff et al., 2015).   
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 The results of Holthoff’s study (Figure 7) found that AD patients in the group 
receiving the exercise intervention showed initial improvements in their executive 
functioning, but after 24 weeks the patients were back to their baseline (Holthoff et al., 
2015).  This was in contrast to patients in the control group who showed a sustained 
decrease in their executive functioning over the entire 24 weeks.  Physical functions 
improved for patients in the experimental group, whereas patients in the control group 
showed no improvement.  Over the 24-week study, the control group displayed a decline 
in their ADL performance, behavior, depression, and anxiety, whereas the patients in the 
intervention group remained stable in these categories.  There were no relevant effects of 
the exercise intervention on global cognition (Holthoff et al., 2015). 
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Figure 7. Effects of exercise intervention.  Each line graph compares the results of the 
control group and the experimental group at the study’s three time points (0, 12, and 24 
weeks).  NPI = Neuropsychiatric Inventory.  (Figure taken from Holthoff et al., 2015.) 
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Nutritional Interventions for Treatment of Patients with Alzheimer’s Disease 
 In recent years, it has become clear that nutrition has a significant effect on 
cognition as we age, and not receiving essential nutrients may increase the risk for 
developing AD (Mi, van Wijk, Cansev, Sijben, & Kamphuis, 2013).  Having a balanced 
diet rich in nutrients required for neuronal health could have an effect on healthy aging 
and could reduce the risk of cognitive decline (Mi et al., 2013; Nelson & Tabet, 2015).  
The vast majority of the studies performed evaluating nutrition and AD have focused on 
the prevention of the disease and the effect of nutritional interventions on disease 
incidence.  Most of these studies have used a healthy population and have studied the 
incidence of cognitive impairment (Nelson & Tabet, 2015).  However, there have been a 
smaller number of randomized control trials on nutritional interventions for patients 
already diagnosed with AD.  In this review of nutritional interventions for AD patients, 
the evidence is examined for interventions involving the Mediterranean diet, vitamins 
B12, B6, and folic acid, vitamin E, and omega-3 fatty acids. 
 
Mediterranean Diet 
 The Mediterranean diet is composed of fruits and vegetables and other plant 
products, olive oil as a primary source of fat, fish, low levels of red meat and poultry, and 
a moderate consumption of wine (Frisardi et al., 2011; van de Rest, Berendsen, 
Haveman-Nies, & de Groot, 2015).  This is the typical diet of the population living 
around the coast of the Mediterranean Sea (Frisardi et al., 2011).  It was found that 
adhering to the Mediterranean diet could potentially be protective against developing AD 
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(Scarmeas, Stern, Mayeux, & Luchsinger, 2006).  In the 2006 study by Scarmeas and 
colleagues, the researchers found that patients who did not closely comply with the 
Mediterranean diet were more likely to acquire AD than those who were able to adhere to 
the diet.   
 There have been fewer studies on the effects of the Mediterranean diet on patients 
currently diagnosed with AD.  However, there was one such study on this topic in 2007 
by Scarmeas, Luchsinger, Mayeux, and Stern.  In this study, 192 patients diagnosed with 
mild or moderate AD were assessed every one and a half years on how well they adhered 
to the Mediterranean diet.  The patients were divided into three equal groups, or tertiles, 
depending on their adherence to the diet (high, middle, and low).  Mortality was 
compared between these three groups (Figure 8).  The results indicated that AD patients 
who were in the middle tertile of adherence lived an average of 1.33 years longer than 
patients in the low tertile, whereas patients in the high tertile lived an average of 3.91 
years longer than patients in the low tertile (Scarmeas et al., 2007).   
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Figure 8. Mortality of Alzheimer’s disease patients and adherence to the 
Mediterranean diet.  AD patients have a lower risk of mortality with a higher adherence 
to the Mediterranean diet.  MeDi = Mediterranean diet.  (Figure taken from Scarmeas et 
al., 2007)  
 
 
 
Vitamins B12, B6, and Folic Acid 
 As observed in the literature, patients with AD tend to have lower levels of 
vitamin B12 and folate (Zheng et al., 2014).  The plasma levels of the amino acid 
homocysteine are controlled by folate, vitamin B12, and vitamin B6 (Engelborghs, 
Gilles, Ivanoiu, & Vandewoude, 2014).  Homocysteine has been found to be neurotoxic 
and is believed to be one of the causes of the symptoms in AD patients (Nelson & Tabet, 
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2015).  The 2014 study by Zheng et al. with 116 participants, investigated the possibility 
that the behavioral symptoms observed in patients with AD may be due to high plasma 
levels of homocysteine.  One group consisted of 40 patients diagnosed with AD who had 
behavioral and psychological symptoms.  A second group consisted of 37 AD patients 
with no behavioral and psychological symptoms, and a third group consisted of 39 
healthy individuals with neither AD nor behavioral and psychological symptoms.  The 
plasma level of homocysteine was measured in each of the participants.  Also, MMSE 
scores were recorded from each participant.  Zheng and colleagues found that all of the 
participants in the AD group with behavioral and psychological symptoms had high 
levels of homocysteine, only some of the participants in the AD group with no symptoms 
had high levels of homocysteine, and none of the healthy group had high levels of 
homocysteine.  Moreover, there was a negative relationship between plasma levels of 
homocysteine and MMSE score.  This last finding indicated that levels of homocysteine 
had a direct correlation with cognitive decline in AD (Zheng et al., 2014).  Although the 
study by Kim and Lee in 2014 supported the results of Zheng et al. (2014) that behavioral 
and psychological symptoms in AD were correlated with plasma homocysteine 
concentration, previous studies had found no correlation (Tabet, Rafi, Weaving, Lyons, & 
Iversen, 2006). 
 In order to regulate the elevated plasma levels of homocysteine, the effect of 
using supplements of B vitamins and folic acid, the synthetic form of folate, was studied 
in patients with mild cognitive impairment (MCI) and AD (Aisen et al., 2008; Kwok et 
al., 2011).  The study by Kwok et al. (2011) investigated the effect of supplementation 
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with an oral dose of vitamin B12 and folic acid on cognitive impairment in patients with 
AD or vascular dementia.  A total of 140 patients were divided into a group receiving the 
vitamin B12 and folic acid supplementation and a group receiving a placebo.  During the 
24-month study, global cognitive function and neuropsychiatric symptoms were assessed, 
and levels of homocysteine, vitamin B12, and folate were measured.  Kwok and 
colleagues found that supplementation with vitamin B12 and folic acid was successful in 
increasing serum levels of vitamin B12 and folate and decreasing plasma levels of 
homocysteine.  However, they were not able to show an effect on cognitive decline 
(Kwok et al., 2011). 
 The larger study, with 409 patients with AD, by Aisen et al. in 2008 found similar 
results.  The experimental group received vitamins B6, B12, and folic acid, while the 
control group was given a placebo.  The study measured the effects of the 
supplementation on the cognitive decline in AD patients.  Although the intervention 
lowered the plasma levels of homocysteine, there was no beneficial effect on the course 
of the disease (Aisen et al., 2008).   
Vitamin E 
 Free radicals are reactive molecules with an unpaired electron that are known to 
cause cellular damage and affect the normal functioning of cells (La Fata, Weber, & 
Mohajeri, 2014).  Vitamin E acts as an antioxidant interacting with free radicals to 
prevent oxidative damage to molecules (Farina, Isaac, Clark, Rusted, & Tabet, 2012).  
Vitamin E is found in common foods such as nuts, oils, and fats (Farina et al., 2012).  
Although vitamin E is made up of a group of lipid-soluble molecules, α-tocopherol is the 
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form of vitamin E most commonly used as a supplement and most abundant in human 
cells (La Fata et al., 2014).  Because the central nervous system is particularly susceptible 
to free radical damage which may contribute to AD, vitamin E has been an obvious 
candidate for AD interventions (Engelborghs et al., 2014). 
 The 2009 study by Lloret et al. investigated the effects of vitamin E 
supplementation in patients with AD.  In this study, 57 patients received a dose of either 
vitamin E or a placebo each day.  This treatment lasted for six months.  Assessments of 
cognitive function of the patients were made at the beginning and at the end of the six-
month trial period.  Lloret and colleagues found that the patients receiving vitamin E 
could be separated into two smaller groups: vitamin E respondents and vitamin E non-
respondents.  The respondents were able to maintain their cognitive function throughout 
the trial.  In contrast, a sharp decrease in cognition was observed in the patients that did 
not respond to vitamin E supplementation.  The cognitive decline in these patients was 
more severe than the placebo group as well.  The findings of this study indicated that 
vitamin E may be a beneficial treatment for patients with AD classified as vitamin E 
respondents but harmful to those classified as non-respondents (Lloret et al., 2009). 
Dysken et al. observed contrasting results in their 2014 study on the effect of 
vitamin E and memantine on patients with mild to moderate AD.  This study had 613 
participants and was much larger than the study by Lloret et al. (2009).  The patients were 
divided into four groups: a group receiving only vitamin E, a group receiving only 
memantine, a group receiving both vitamin E and memantine, and a placebo group 
receiving neither intervention.  Dysken and colleagues assessed the participants using 
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measurements of ability to perform ADLs, global cognitive functioning, neuropsychiatric 
symptoms, caregiver burden, and functional dependence.  At the conclusion of the study, 
the researchers found that the patients receiving vitamin E alone declined at a slower rate 
than patients in the three other groups as measured by the ability to perform ADLs.  
There were no significant differences observed for any of the other assessed outcomes, 
but there was a trend towards less decline of these measures when compared with the 
placebo group.  Maintaining the ability to perform ADLs is beneficial for both economic 
cost and quality of life.  Because vitamin E supplementation is very inexpensive, Dysken 
et al. (2014) noted that this intervention is likely to be economical.   
 
Omega-3 Fatty Acids 
 Lipids are one of the main components of the central nervous system (CNS).  In 
particular, omega-3 fatty acids play a large role in the normal function of the brain.  High 
levels of omega-3 fatty acids are found in fish (Cederholm, Salem, & Palmblad, 2013).    
The most common omega-3 fatty acid in the brain is docasahexaenoic acid (DHA), which 
is a major component of neuronal membranes.  Eicosapentaenoic acid (EPA) is another 
common omega-3 fatty acid that has a functional role in the central nervous system (Wu 
et al., 2015).  Because of the important role of omega-3 fatty acids in the brain, it has 
been suggested that increasing the amount of omega-3 fatty acids in the diet may play a 
protective role in cognitive decline and may be beneficial for patients diagnosed with AD 
(Nelson & Tabet, 2015).  There have been a number of clinical trials which were 
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performed to investigate the effect of omega-3 fatty acids on patients with AD (Chiu et 
al., 2008; Phillips, Childs, Calder, & Rogers, 2015; Quinn et al., 2010). 
 The 2008 study by Chiu et al. examined the effectiveness of an omega-3 
polyunsaturated fatty acid (PUFA) supplementation as a means to slow the decline in 
patients with AD and MCI.  Forty-six patients randomly placed in two groups, with one 
group receiving a dose of omega-3 PUFAs and the other group receiving an olive oil 
placebo were assessed periodically throughout the 24-week study.  The researchers 
measured the patient’s global cognitive function using ADAS-cog and MMSE, clinical 
condition using the Clinician’s Interview-Based Impression of Change scale (CIBIC-
plus), and depression using the Hamilton Depression Rating Scale (HDRS).  Chiu and 
colleagues found that there was a beneficial effect on the CIBIC-plus score for the 
experimental group taking omega-3 PUFAs.  There was no significant effect on either of 
the global cognition scales (ADAS-cog and MMSE); however, it was found that the 
participants with MCI showed a statistically significant improvement in ADAS-cog 
scores.  From these results, the researchers concluded that omega-3 fatty acids potentially 
had a beneficial effect on clinical condition in AD and MCI patients.  Furthermore, 
although no effect was found on cognition in AD patients, omega-3 fatty acids might 
have a beneficial cognitive effect in patients with MCI and very early AD (Chiu et al., 
2008).  
 The study by Quinn et al. in 2010 investigated the effects of supplementation with 
DHA on patients with mild to moderate AD.  In this study, 402 AD patients were 
assigned to two groups: one group of 238 receiving a supplement of DHA and one group 
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of 164 receiving a placebo.  The purpose of the study was to observe the effect of DHA 
on the decline of cognitive function and functional ability.  The treatment was 
administered to the participants for 18 months, with assessments occurring throughout the 
trial period.  During these assessments, the researchers investigated the participant’s 
global cognition, ability to perform ADLs, neuropsychiatric symptoms, and quality of 
life.  Brain volume was evaluated in a smaller group.  The results of the study indicated 
that there was no detectable beneficial effect in patients taking the supplement of DHA 
compared with the control group for any outcomes.  In the smaller group of patients 
receiving magnetic resonance imaging (MRI) to investigate the effect of DHA on brain 
volume, there was no slowing of brain atrophy with the supplementation of DHA (Quinn 
et al., 2010).   
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DISCUSSION 
 
Cognitive Interventions for Alzheimer’s Disease 
Based on the definitions from Borisovskaya et al. (2014), the interventions used 
by four of the seven reviewed studies tested a cognitive training (CT) intervention (Cahn-
Weiner et al., 2003; Davis et al., 2001; Loewenstein et al., 2004; Niu et al., 2010).  Two 
studies qualified as cognitive rehabilitation (CR) interventions (Clare et al., 2010; Kim, 
2015), and one qualified as a cognitive stimulation (CS) intervention (Olazarán et al., 
2004).  All seven studies reported some benefits to the tested intervention, but most 
showed mixed and modest results.   
 Although the cognitive training studies of Davis et al. (2001), Cahn-Weiner et al. 
(2003), and Loewenstein et al. (2004) described benefits in recall with regard to face-
name associations, it is unknown whether these benefits transfer to real-life situations or 
how long these effects last after the study.  Also, there were no neuropsychiatric or ADL 
benefits found in any of these studies.  On the other hand, the study by Loewenstein et al. 
(2004) showed evidence of benefits in practical functional skills such as paying bills and 
making change, which may benefit real-life scenarios.  Unlike the other three cognitive 
training studies, Niu et al. (2010) showed possible benefits for neuropsychiatric 
symptoms, specifically with apathy and depression, unveiling a possible clinically 
relevant benefit to cognitive training.  Furthermore, the results showed an improvement 
in MMSE for the group receiving cognitive training, which may indicate a possible 
benefit for global cognition (Niu et al., 2010). 
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 The cognitive stimulation therapy by Olazarán et al. (2004) was the longest of the 
reviewed studies, lasting a full year.  Over the year, AD patients were able to maintain 
ADAS-cog, a global cognition score, and improve in GDS score (J. Olazarán et al., 
2004).  The result that cognition was maintained despite the inevitable cognitive decline 
that comes with AD is evidence for a clinically relevant benefit for cognitive stimulation 
therapy. 
 The studies by Clare et al. (2010) and Kim (2015) both tested the effects of 
cognitive rehabilitation; however, the study by Kim tested cognitive rehabilitation in 
combination with cognitive training exercises.  Both of these studies found an 
improvement in goal performance and satisfaction.  In addition, Clare et al. (2010) found 
that the experimental group had a higher memory performance during the six-month 
follow-up after the completion of the trial.  Because of the individualized, goal-orientated 
nature of cognitive rehabilitation, the benefits found in cognitive rehabilitation may 
transfer more easily to real-life settings. 
 Even though the benefits of cognitive intervention were mixed and often modest, 
it is clear that benefits do exist.  Six of the reviewed trials had interventions lasting just 5-
12 weeks (Cahn-Weiner et al., 2003; Clare et al., 2010; Davis et al., 2001; Kim, 2015; 
Loewenstein et al., 2004; Niu et al., 2010), whereas only one study had an intervention 
lasting an entire year (Olazarán et al., 2004).  Therefore, it may be the case that stronger 
and more lasting benefits can be seen during longer-term studies.  Additionally, none of 
the seven studies discussed the cost of cognitive interventions.  Because cost is very 
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important when deciding which intervention to choose, more research on the cost 
effectiveness of cognitive interventions for AD is necessary.   
Finally, six of the seven reviewed studies indicated that the AD patients were 
taking cholinesterase inhibitors (Cahn-Weiner et al., 2003; Clare et al., 2010; Davis et al., 
2001; Kim, 2015; Loewenstein et al., 2004; Niu et al., 2010; Olazarán et al., 2004), and 
the remaining study did not disclose any information (Kim, 2015).  It is unclear if the 
results of these cognitive intervention studies would change if cholinesterase inhibitors 
were not used; although ethically this question may not be answerable. 
 Due to the modest benefit seen in the cognitive interventions reviewed, more 
research is necessary before cognitive interventions can be utilized daily for the treatment 
of patients with AD.  
 
Exercise Interventions for Alzheimer’s Disease 
Out of the seven exercise intervention studies reviewed, six of them reported that 
there was some kind of benefit in physical function for the group receiving the exercise 
intervention (Holthoff et al., 2015; Miu et al., 2008; Rolland et al., 2007; Steinberg et al., 
2009; Venturelli et al., 2011; Vreugdenhil et al., 2012).  This benefit in the physical 
function of patients with AD may indicate an improvement in the ability to perform 
activities of daily living.  In fact, five of the seven studies used an assessment of the 
patient’s ability to perform ADLs, and in these five studies an ADL benefit was found for 
patients receiving the intervention (Holthoff et al., 2015; Rolland et al., 2007; Steinberg 
et al., 2009; Venturelli et al., 2011; Vreugdenhil et al., 2012).  Therefore, this review of 
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these seven studies suggests that an exercise program can significantly improve or at least 
slow the deterioration in physical ability and capacity to perform ADLs that is normally 
characteristic of patients with AD. 
 Next, five of the seven exercise intervention studies assessed the effect of exercise 
on the global cognition of the participants (Holthoff et al., 2015; Miu et al., 2008; 
Steinberg et al., 2009; Venturelli et al., 2011; Vreugdenhil et al., 2012).  Out of these five 
studies, Venturelli et al. found a slowing of the cognitive decline, and Vreugdenhil et al. 
found increased cognition for the groups receiving the exercise intervention (Venturelli et 
al., 2011; Vreugdenhil et al., 2012).  In the other three studies that assessed the cognition 
of the participants, the exercise programs had no effect on cognition (Holthoff et al., 
2015; Miu et al., 2008; Steinberg et al., 2009).  Because of these mixed results, no 
conclusion can be drawn about whether exercise interventions have a beneficial effect on 
global cognition for patients with AD. 
 Furthermore, studies have shown that exercise may have a protective effect 
against depression in patients with AD (Regan, Katona, Walker, & Livingston, 2005).  
Out of the seven studies reviewed, five assessed the participants for changes in 
depression (Holthoff et al., 2015; Miu et al., 2008; Rolland et al., 2007; Steinberg et al., 
2009; Vreugdenhil et al., 2012).  Only two of these five studies showed that an exercise 
intervention had a beneficial effect on depression (Holthoff et al., 2015; Vreugdenhil et 
al., 2012).  Therefore, it is difficult to form an opinion about the impact of exercise on 
depression in AD patients. 
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 The role that dementia medication like cholinesterase inhibitors and memantine 
play in the results of these seven studies is also unclear.  Holthoff and colleagues reported 
that all of the participants used in their study were taking either cholinesterase inhibitors, 
memantine, or both (Holthoff et al., 2015).  Three other studies stated that a portion of 
their participants were taking cholinesterase inhibitors (Miu et al., 2008; Rolland et al., 
2007; Vreugdenhil et al., 2012).  The other three studies did not mention whether the 
participants were taking dementia medication during the test (Cott et al., 2002; Steinberg 
et al., 2009; Venturelli et al., 2011).  Because of this inconsistency, it may prove 
beneficial to evaluate the effect of an exercise intervention on AD patients with and 
without the use of dementia medication. 
 The lack of harmful side effects, the significant benefits on ADL and quality of 
life, and the cost effectiveness of home-based exercise programs are important factors 
which make exercise interventions a practical method for managing AD.  
 
Nutritional Interventions for Alzheimer’s Disease 
Although the research on the effects of the Mediterranean diet for patients with 
AD is lacking, the results from the study by Scarmeas et al. (2007) indicated a beneficial 
effect on mortality.  It is clear that more research is necessary to verify this effect on 
patients with AD.  Because maintaining a Mediterranean diet is safe, relatively easy, and 
potentially beneficial, it is a practical option for use in patients with AD.  
Regardless of the negative results from the studies by Kwok et al. (2011) and 
Aisen et al. (2008), there is no doubt that supplementation with vitamins B12, B6, and 
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folic acid has a significant effect on the plasma level of homocysteine.  As a result, more 
research needs to be done to investigate the possible benefits on patients with AD. 
 Based on the conflicting results of the two studies by Lloret et al. (2009) and 
Dysken et al. (2014), it is clear that more research on vitamin E supplements is necessary.  
If it is true that supplementation with vitamin E is a clinically beneficial intervention for 
patients with AD, then it seems worthwhile to pursue because of the inexpensive cost of 
vitamin E.  On the other hand, additional scrutiny is necessary as a result of the finding 
that supplementation with vitamin E may potentially harm some AD patients. 
Although the theory behind supplementation with omega-3 fatty acids in AD 
patients is logical, the clinical trials to date do not show compelling evidence for their use 
in slowing the decline in AD.  However, because of the positive results found in some 
studies, further research is justified. 
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CONCLUSIONS 
 
 Although the three reviewed nonpharmacological interventions for AD—
cognitive, exercise, and diet—found only modest benefits, some are promising, clinically 
relevant, and easy to put into practical use. 
 The cognitive intervention that had the most significant results was cognitive 
rehabilitation.  This finding may be a result of the personalized approach taken by 
cognitive rehabilitation to focus on the needs and goals of each individual patient.  It may 
be that focusing on each patient better prepares the individual to face his or her personal 
challenges.  Although benefits of cognitive training and cognitive stimulation also were 
observed, the results were often modest and mixed.   
 Next, even though most exercise interventions did not have an effect on the 
cognitive decline characteristic of Alzheimer’s disease, most interventions were able to 
produce beneficial results in terms of physical function or ability to perform activities of 
daily living.  Because much of the economic and social cost of Alzheimer’s disease 
comes from the patients’ inability to care for themselves, these positive findings 
regarding the physical functioning of AD patients are beneficial for the quality of life of 
the patients as well as their families.  It is clear that exercise interventions are ready for 
implementation into widespread practice.  
 Finally, the results of the diet interventions were difficult to interpret given the 
mixed results of the reviewed clinical trials.  However, there seem to be beneficial effects 
of maintaining the Mediterranean diet. 
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 In conclusion, there are potentially significant clinical benefits from the three 
nonpharmacological interventions.  With the increasing number of patients with 
Alzheimer’s disease and the relatively few successful treatments available to these 
patients, more research on nonpharmacological interventions is warranted. 
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FUTURE PLANS 
  
Modest positive results were observed for all three nonpharmacological 
interventions reviewed; therefore, future studies are warranted on each of the three 
methods.  More specifically, future randomized control trials are critical to verify the 
beneficial effects observed for cognitive rehabilitation.  In addition, it was clear from the 
literature that exercise interventions for patients with AD had a positive effect on the 
ability of patients to perform ADLs, but it was unclear whether there was a specific effect 
on cognition.  Consequently, further trials are essential to study the effect of exercise on 
cognition.  Additionally, the Mediterranean diet was reported to have a beneficial effect 
on patients with AD; however, research on this topic was lacking and future trials are 
recommended.   
In most of the studies reviewed in this thesis, the patients with AD were taking 
cholinesterase inhibitors throughout the duration of most experimental trials.  This 
situation is not surprising because cholinesterase inhibitors are one of the few proven 
dementia medications.  However, it would prove informative to observe the results of 
each nonpharmacological intervention without the use of cholinesterase inhibitors to 
complicate the findings.   
Lastly, an intervention combining cognitive, exercise, and nutritional 
interventions is a warranted strategy.  It would be interesting to observe the overall effect 
on global cognition as well as quality of life for patients with AD of a combinatorial 
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intervention including cognitive rehabilitation, moderate exercise, and a controlled 
Mediterranean diet. 
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